Integra Capital Surpluse from 2010 to 2025

IART Stock  USD 22.18  0.46  2.03%   
Integra LifeSciences Capital Surpluse yearly trend continues to be comparatively stable with very little volatility. Capital Surpluse will likely drop to about 1 B in 2025. From the period from 2010 to 2025, Integra LifeSciences Capital Surpluse quarterly data regression had r-value of  0.87 and coefficient of variation of  29.78. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-06-30
Previous Quarter
1.2 B
Current Value
1.3 B
Quarterly Volatility
279 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Integra LifeSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Integra LifeSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 147.9 M, Interest Expense of 74.2 M or Total Revenue of 1.7 B, as well as many indicators such as Price To Sales Ratio of 1.03, Dividend Yield of 3.0E-4 or PTB Ratio of 1.07. Integra financial statements analysis is a perfect complement when working with Integra LifeSciences Valuation or Volatility modules.
  
Check out the analysis of Integra LifeSciences Correlation against competitors.

Latest Integra LifeSciences' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Integra LifeSciences Holdings over the last few years. It is Integra LifeSciences' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Integra LifeSciences' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Integra Capital Surpluse Regression Statistics

Arithmetic Mean995,716,075
Geometric Mean951,278,471
Coefficient Of Variation29.78
Mean Deviation258,990,691
Median1,028,691,654
Standard Deviation296,549,192
Sample Variance87941.4T
Range916.3M
R-Value0.87
Mean Square Error22219.4T
R-Squared0.76
Slope54,450,475
Total Sum of Squares1319121.4T

Integra Capital Surpluse History

2025B
20241.5 B
20221.3 B
20211.3 B
20201.3 B
20191.2 B
20181.2 B

About Integra LifeSciences Financial Statements

Integra LifeSciences shareholders use historical fundamental indicators, such as Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Integra LifeSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Integra LifeSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Integra LifeSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse1.5 BB

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.